ALKEM5,111.00

Alkem Laboratories Ltd.

· Pharma & Health
₹ CrorePeersMANKINDTORNTPHARMIPCALABLUPINFORTISAUROPHARMALAURUSLABSBIOCONMcap ₹61,102 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)294.83310.05341.23341.23
Receivable Days (DSO)64.9169.4373.9173.91
Payable Days (DPO)193.67195.14229.74224.52
Cash Conversion Cycle (days)166.07184.34185.40190.62
Working Capital Turnover1.971.891.982.03
Asset Turnover0.810.730.700.70
Cash Conversion (CFO/Net Income)1.080.860.830.83
CFO/EBITDA0.870.760.650.65
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.